Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell ...

High School DxD is back in the headlines. It was just a matter of time before the hit harem title made a comeback, and now, fans are keeping watch on the horizon. After all, it was not long ago ...

Beloved harem High School DxD is finally getting a follow-up after 10 years. High School DxD is considered the premier example of the harem genre, especially its fan-service-oriented cohort.

High School DxD made a surprising return to screens with one of the wildest anime cameos of the year. High School DxD was last seen with the release of the fourth season, High School DxD Hero ...

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial ...

Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed.

Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

Managing adverse events with trastuzumab deruxtecan (Enhertu) in real-world clinical practice is proving trickier than would have been anticipated from clinical trial reports.